The International Society for Pharmacoepidemiology (ISPE) gratefully acknowledges the generous support of the following organizations and institutions. Their contributions helped to enhance the scientific program content and increase attendance at the ICPE 2007. Thank you.

Academic Showcase/Welcome Reception Sponsors
- Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
- College of Pharmacy, University of Texas
- Drug Safety Research Unit, University of Portsmouth
- Pharmaceutical Health Services Research, University of Maryland, Baltimore
- Slone Epidemiology Center, Boston University
- University of North Carolina at Chapel Hill
- Division of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences

Exhibitors (as of July 23, 2007)
- Cerner Corporation
- DrugLogic, Inc.
- GPRD
- i3 Drug Safety
- IMS Health
- John Wiley & Sons
- Kendle
- Outcome
- PHARMO Institute
- Phase Forward
- Pharmides Research
- RTI Health Solutions
- The Uppsala Monitoring Centre
- Thomson Healthcare
- TrialStat Corporation
- United BioSource Corporation
- Uniform Data System
- Wolters Kluwer Health

ANNUAL MEETING SPONSORS (as of July 23, 2007)

Platinum: $12,000
- John Wiley & Sons
- Pfizer

Gold: $6,000
- Amgen
- Eli Lilly and Company
- Genentech, Inc.
- GlaxoSmithKline
- i3 Drug Safety
- Kendle
- Merck Research Laboratories
- Pharmaceutical Research Associates
- Proctor & Gamble Pharmaceuticals
- Roche
- RTI Health Solutions
- United BioSource Corporation
- Wyeth

Silver: $3,000
- Astra Zeneca Canada
- Genzyme
- HealthCore
- PharmaNet
- Sanofi Pasteur

Bronze: $1,500
- Allergan
- Cephalon
- DrugLogic, Inc.
- GPRD
- Outcome
- Risk Management Resources

IN THIS PROGRAM

23rd ICPE Agenda
- Saturday ............................................................. 7
- Sunday .............................................................. 8
- Monday ............................................................. 9
- Tuesday ............................................................. 17
- Wednesday ....................................................... 26

23rd ICPE Posters
- Poster Presentation Guidelines ............................ 30
- Poster Session A .................................................. 32
- Poster Session B .................................................. 40
- Poster Session C .................................................. 49

23rd Abstract Index
- Abstract Index .................................................... 57
AGENDA: Saturday, August 18

8:30am - 5:30pm / Hilton Courville/Montmorency / ISPE Board of Directors Meeting

Noon - 5:00pm / Centre Foyer 4 / Registration

PRE-CONFERENCE EDUCATIONAL SESSION

1:00 - 5:00pm / Centre Room 205AB / Introduction to Pharmacoepidemiology
(*Registration required; included as part of the full meeting registration)

Chair: Andrew McAfee
- James Lewis, Case-Control Studies
- Andrew McAfee, Cohort Studies
- Syed Rizwanuddin Ahmad, FISPE, Spontaneous Reporting
- Eileen Ming, Confounding by Indication

5:00 - 7:00pm / Centre Foyer 2 / Student Meet and Greet
(Meet at ISPE Registration Desk at 5:00 pm, then to Old Montreal Bar)
- Open to all students.
- Organized by the ISPE Student Council.

7:00 - 10:00pm / ISPE Board of Directors Dinner (By Invitation)

2007
ISPE’s Second Asian Meeting
Convened in conjunction with the Japanese Society for Pharmacoepidemiology
October 26-27, 2007
Tokyo, Japan

2008
ISPE Mid-Year Meeting
April 26-29, 2008
Radisson Hotel Boston
Boston, Massachusetts, USA

24th ICPE
August 17-20, 2008
Bella Centre
Copenhagen, Denmark

2009
ISPE Mid-Year Meeting
April, TBD
Stockholm, Sweden

25th ICPE
August 16-19, 2009
Rhode Island Convention Center
Providence, Rhode Island, USA

Visit the ISPE website, www.pharmacoepi.org, for meeting updates and information.

BADGES
All attendees at ICPE 2007 must wear their name badges to ALL events.

A badge will be needed for admission to meeting related functions such as the scientific sessions, the exhibit/poster hall, and social events. Badges will be included in the registration packet material. In some cases, tickets will be required.

Badge Legend
- Student = Yellow
- New Member = Blue
- One Day Attendee = Red

Room Legend
- Centre = Quebec City Convention Centre
- Hilton = Quebec Hilton Hotel
AGENDA: Sunday, August 19

8:00am - 6:00pm / Centre Foyer 4 / Registration

8:00am - 5:00pm / Centre 201C / Speakers' Ready Room

PRE-CONFERENCE EDUCATIONAL SESSIONS

8:30am - 12:00pm / Centre 205AB / Introduction to Therapeutic Risk Management
(*Admission by ticket only. Tickets will be included in registration materials for those who registered for this session.)

Co-Chairs: Elizabeth Andrews, FISPE & Carla van Bennekom

• Elizabeth Andrews, FISPE, Introduction to Therapeutic Risk Management
• Carla van Bennekom, Examples of Risk Management Programs and Evaluations
• Judith Jones, FISPE, Developing Risk Minimization Action Plans

8:30am - 12:00pm / Centre 302AB / Introduction to Drug Utilization/Health Services Research
(*Admission by ticket only. Tickets will be included in registration materials for those who registered for this session.)

Chair: Robert Vander Stichele

• Robert Vander Stichele, Methodological Framework and Tools for Cross-National Comparisons of Drug Utilization Data
• Morten Anderson, Assessing Validity of Prescribing Quality Indicators
• Monique Elseviers, DUR and Pharmacoepidemiology: Case Study — Analgesic Nephropathy
• Sebastian Schneeweiss, FISPE, Time Trend Analysis for Program Evaluation

8:30am - 12:00pm / Hilton Beaumont/Beauport/Belair / Skills Workshop – Students Only*
(*Registration required; included as part of full meeting registration.)

Chair: Chris Delaney, Chair, Student Council

• Toine Egberts, FISPE, Outcome Assessment: Databases vs. Clinical Data
• Lucie Blais, Channeling and Confounding by Indication
• Linda Levesque, Reverse Protopathic Bias
• Tjeerd van Staa, Two Answers from the Same Data Source

Noon - 1:30pm
Lunch – on your own

Noon - 1:30pm / Hilton Plaines/Citadelle / Luncheon for New Members/Student Prize Winners/Scholarship Recipients
(By Invitation)
AGENDA: Monday, August 20

7:00 - 8:00am / Centre 400A / Poster Session A Set-up

7:00 - 8:00am
ISPE Committee Meetings
Open to all interested participants.
- Education / Hilton Montmorency / Finance / Hilton Courville /

7:30am - 6:00pm / Centre Foyer 4 / Registration

8:00am - 5:00pm / Centre 201C / Speakers’ Ready Room

8:00am - 5:00pm / Centre 400A / Exhibits/Posters

OPENING SESSION
8:30 - 10:00am / Centre 200AB / Welcome
- Jean-Pierre Grégoire, Chair, Scientific Program Committee
- Jocelyne Moisan, Chair, Local Host Committee

Presidential Address
- Allen A. Mitchell, FISPE, ISPE President

Keynote Address
- Norman Fost, The Dysregulation of Research

10:00 - 10:30am / Centre 400A / Break/Posters/Exhibits

Our work is someone’s hope. Join us.

MRL Epidemiology - Improving research to assess patient outcomes. Our mission is the scientific study of disease, endpoints and patient outcomes to evaluate the benefits and risks of our products. At Merck, we pride ourselves on meeting patient expectations – leveraging the most complete data and a strong cohesive effort to make the products that make life better.

Our Epidemiology Department represents that kind of diligence, establishing safety and efficacy claims through innovative approaches to medical development. We provide epidemiologic and outcomes research for all Merck drugs and vaccines. Using existing information, database analyses and conducting epidemiology studies across the globe, we characterize disease natural history for new therapeutic areas, assist in clinical trial design based on the epidemiology of the disease, link biomarkers to outcomes and help understand the safety of our products pre- and post-launch. Our team is an active member of clinical development and outcomes research teams.

Merck is a global research-driven pharmaceutical company dedicated to putting patients first in all we do. That philosophy was first articulated by George Merck and it still guides us today. Join our Epidemiology Department and participate in our investigative design and interpretation that enable us to bring life-enhancing products to market. Visit merck.com/careers to find out how.

Merck is an equal opportunity employer, M/F/D/V – proudly embracing diversity in all of its manifestations.
### 10:30am - Noon

**CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

<table>
<thead>
<tr>
<th>Methods I / Centre 200AB</th>
<th>Moderators: Miriam Sturkenboom &amp; Annie Hutchinsom</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10:30am</strong></td>
<td></td>
</tr>
<tr>
<td>• The Use of the Overlapping Coefficient in Propensity Score Analysis [1]</td>
<td>Edwin P Martens, Wiebe R Pestman, Anthonius de Boer, Svetlana V Beitzser, Olaf H Klungel. (Netherlands)</td>
</tr>
<tr>
<td><strong>10:45am</strong></td>
<td></td>
</tr>
<tr>
<td>• Multilevel Confounding in Pharmacoepidemiologic Research: An Application of Propensity Score Methods [2]</td>
<td>Andrea Gruneir, Kate L Lapane, Susan C Miller, Vincent Mor. (United States)</td>
</tr>
<tr>
<td><strong>11:00am</strong></td>
<td></td>
</tr>
<tr>
<td><strong>11:15am</strong></td>
<td></td>
</tr>
<tr>
<td>• Using Imputation to Control Unmeasured Confounding: An Internal Validation Study [4]</td>
<td>Til Stürmer, Sebastian Schneeweiss, Kenneth J Rothman, Jerry Avorn, Robert J Glynn. (United States)</td>
</tr>
<tr>
<td><strong>11:30am</strong></td>
<td></td>
</tr>
<tr>
<td><strong>11:45am</strong></td>
<td></td>
</tr>
<tr>
<td>• When Patients Are Treated Contrary to Prediction – Implications for Use of Propensity Scores in Extreme Cases [6]</td>
<td>Til Stürmer, Sebastian Schneeweiss, Kenneth J Rothman, Jerry Avorn, Robert J Glynn. (United States)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk Assessment in Commonly Used Drugs / Centre 205AB</th>
<th>Moderators: Joanna Haas &amp; Maureen Cronin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10:30am</strong></td>
<td></td>
</tr>
<tr>
<td>• Traffic Accident Risks Associated with the Prescription of Medicinal Drugs: A Registry-Based Cohort Study [25]</td>
<td>Svetlana Skurtveit, Jorg Morland, Jorgen Bramness, Ineke Neutel, Ingebjorg Gustavsen, Liliana Bachs, Anders Engeland. (Norway)</td>
</tr>
<tr>
<td><strong>10:45am</strong></td>
<td></td>
</tr>
<tr>
<td>• The Safety and Efficacy of Oral Contraceptives in Teenagers: Results from the EURAS-OC Study [26]</td>
<td>Juergen C Dinger, Anita Assmann, Lothar AJ Heinemann, Doerthe Kuehl-Habich. (Germany)</td>
</tr>
<tr>
<td><strong>11:00am</strong></td>
<td></td>
</tr>
<tr>
<td>• Use of Thiazide Diuretics and Risk of Hip/Femur Fracture: A Population-Based Case-Control Study and a Meta-Analysis of Double Blinded RCTs [27]</td>
<td>Frank de Vries, Brahm Thio, Kadir Ozer, Didem Altug, Hubert Leufkens, Tjeerd van Staa. (Netherlands)</td>
</tr>
<tr>
<td><strong>11:15am</strong></td>
<td></td>
</tr>
<tr>
<td>• The Prevalence of Antipsychotic Use among Privately Insured Patients Ages 0-64: Implications for Education and Safety Studies [28]</td>
<td>Tami Mark, Stella Chang, Leigh Hansen. (United States)</td>
</tr>
<tr>
<td><strong>11:30am</strong></td>
<td></td>
</tr>
<tr>
<td>• Lipid Lowering Therapy and the Risk of Parkinson’s Disease [29]</td>
<td>Claudia Becker, Jick S Susan, Christoph R Meier. (Switzerland)</td>
</tr>
<tr>
<td><strong>11:45am</strong></td>
<td></td>
</tr>
<tr>
<td>• The Risk of Death with Concurrent Use of Cholinesterase Inhibitors and Anticholinergics/Antipsychotics in Alzheimer’s Disease [30]</td>
<td>Alison Supina, David Hogan, Scott Patten, Joseph Amuah, Winanne Downey, Patricia Beck, Colleen Maxwell. (Canada)</td>
</tr>
</tbody>
</table>
Risk of Antidepressants: I've Got Plenty of Nothing / Centre 301AB /  
Moderators: Julie Zito & Patrice Verpilliat

10:30am  
- Risk of Cerebrovascular Diseases Associated with Antidepressant Use in Patients with Depression: A Population-Based Case-Control Study [13]  
Yan Chen, Nick C Patel, Hong Li, Lawson Wulsin, Jeff J Guo. (United States)

10:45am  
- Venlafaxine Use Was Not Associated with an Increased Risk of Sudden Cardiac Death [14]  
Daniel Mines, Bruce Fireman, Janel Lee, Alan S Go. (United States)

11:00am  
- Use of Antidepressive Agents and the Risk of Diabetes: A Nested Case Control Study [15]  
Frank Andersohn, René Schade, Samy Suissa, Edeltraut Garbe. (Germany)

11:15am  
- Risks of Suicide and Poisoning among Elderly Patients Prescribed Selective Serotonin Reuptake Inhibitors: A Retrospective Cohort Study [16]  
Elham Rahme, Kaberi Dasgupta, Gustavo Turecki, Hacene Nedjar, Guillaume Galbaud du Fort. (Canada)

11:30am  
- Gastrointestinal Bleed Risk with the Use of Selective Serotonin Receptor Antagonists: A New Look [17]  
Lucie Opatrny, JA Delaney, Samy Suissa. (Canada)

11:45am  
- Antidepressants and Risk of Prostate Cancer: A Nested Case-Control Study [18]  
Hani M Tamim, Salaheddin Mahmud, Jean-Francois Boivin, James A Hanley, MaryRose Stang, Jean-Paul Collet. (Saudi Arabia)

Cancer / Centre 302AB /  
Moderators: Michael Cook & Alec Walker, FISPE

10:30am  
- Selective Serotonin Reuptake Inhibitors (SSRIs) and Breast Cancer: Preliminary Results of a Two-Stage Case-Control Study [19]  
Janet Ashbury, Will King, Patricia Beck, Kristian Aronson. (Canada)

10:45am  
- Meta-Analysis of the Effects of Aspirin, NSAID and Acetaminophen Use on Prostate Cancer Risk [20]  
SM Mahmud, D Turner, E Franco, A Aprikian. (Canada)

11:00am  
- Cox-2 Selective Inhibitors, Other Non-Steroidal Anti-Inflammatory Drugs, and the Risk of Breast Cancer [21]  
Deirdre P Cronin-Fenton, Lars Pedersen, Søren Friis, Timothy L Lash, John A Baron, Henrik Toft Sørensen. (Denmark)

11:15am  
- Renal Impairment in Cancer Patients Following Intravenous (IV) Zoledronic Acid or IV Ibandronate Treatment [22]  
Ingo J Diel, Rudolf Weide, Hubert Köppler, Lucia Antrás, Michael Smith, Jesse Green, Neil Wintfeld, Maureen Neary, Mei Sheng Duh. (United States)

11:30am  
- The Effect of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on Non-Melanoma Skin Cancer (NMSC) Incidence in the SKICAP-AK Trial [23]  
Mary C Clouser, Robin B Harris, Denise J Roe, Janet A Foote. (United States)

11:45am  
- Risk of Lymphoma Risk among Users of Topical Corticosteroids and Topical Calcineurin Inhibitors. Preliminary Results [24]  
Felix M Arellano, Alejandro Arana, Charles E Wentworth, Carlos Fernandez-Vidaurre, Raymond Schlienger, Eulogio Conde. (Spain)
### Drug Use and Diabetes Progression / Centre 303AB /

**Moderators:** Jeffrey Johnson & Cindy Girman

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:30am | • Use of ACE Inhibitors and Angiotensin Receptor Blockers by Elderly with Type 2 Diabetes in Quebec [7]  
Caroline Sirois, Jean-Pierre Gregoire, Jocelyne Moisan. (Canada) |
| 10:45am | • Variation in Diabetes Drug Utilization among Medical Facilities in the Veterans Health Administration (VHA) [8]  
Kristijan H Kahler, Mangala Rajan, George G Rhoads, Monika M Safford, Kitaw Demissie, Shou-En Lu, Leonard M Pogach. (United States) |
| 11:00am | • Passage to Insulin in Elderly with Type 2 Diabetes [9]  
Norma Perez, Jocelyne Moisan, Caroline Sirois, Jean-Pierre Gregoire. (Canada) |
| 11:15am | • Immortal Time Bias in an Observational Study of the Progression of Type 2 Diabetes [10]  
Linda E Levesque, Abbas Kezouh, Samy Suissa. (Canada) |
| 11:30am | • Rates of Hypokalemia after Implementation of Aggressive Insulin Dosing in Critical Care Patients [11]  
Ahunna J Onyenwenyi, Almut G Winterstein. (United States) |
| 11:45am | • Association between Use of Thiazolidinediones, Other Oral Antidiabetics and Psoriasis [12]  
Yolanda B Brauchli, Susan S Jick, Christoph R Meier. (Switzerland) |

---

**Noon - 1:30pm**

**Lunch/Poster Session A/Exhibits** / Centre 400A / Sponsored by United BioSource Corporation

**ISPE Committee/Council Meetings**

Open to all participants. (Lunch will be available in meeting rooms)

- Bylaws / Hilton Bernieres / Fellowship & Awards / Hilton Beaumont / Public Policy / Hilton Belair / Student Council / Hilton Beauport /
### AGENDA: Monday, August 20

#### 1:30 - 3:00pm
**CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

**Drug Utilization in the Elderly**
/ Centre 200AB /  
**Moderators:** Ulf Bergman, FISPE, & Andrew Gilbert

- **1:30pm**  
  - Lower Use of Chemotherapy among Older Adult Patients with Metastatic Colorectal Cancer (mCRC) in the US [31]  
  W Dong, M Taylor, M Sugrue. (United States)

- **1:45pm**  
  - Medication Prescribing for Institutionalized Demented Elderly [32]  
  Monique M Elseviers, Robert H Vander Stichele. (Belgium)

- **2:00pm**  
  - Does Receiving Care in a Nursing Home Dementia Special Care Unit Decrease the Likelihood of Receiving Psychotropic Medications for Residents with Dementia? [33]  
  Andrea Gruneir, Kate L Lapane, Susan C Miller, Vincent Mor. (United States)

- **2:15pm**  
  - Exposure of the Elderly to Potential Nephrotoxic Drug Combinations in Belgium [34]  
  Johan FF De Haes, Hilde LE Smets, Philippe G Jorens, André De Swaef, Gert A Verpooten. (Belgium)

- **2:30pm**  
  - Patterns of Prescription Medication Utilization among the US Non-Institutionalized Elderly Population [35]  
  Brian J Quilliam, Jonathan T Weiner, Rita M Marcoux. (United States)

- **2:45pm**  
  - The Relationship between Number of Drugs and Drug-Drug Interactions in the Elderly [36]  
  Kristina Johnell, Inga Klarin. (Sweden)

**Pharmacogenomics and Drug Effects - It’s in the Genes**
/ Centre 205AB /  
**Moderator:** Steve Kimmel, FISPE

- **1:30pm**  
  - Interactions between the Gly460Trp Alpha-Adducin Gene Variant and Diuretics and the Risk of Myocardial Infarction among Treated Hypertensive Patients [49]  
  Diane BMA van Wieren-de Wijer, Anke-Hilse Maitland-van der Zee, Anthonius de Boer, Bruno Ch Stricker, Olaf H Klungel. (Netherlands)  
  *Student Award Recipient – Edlavitch Award*

- **1:45pm**  
  - Increased QTc Shortening to Digoxin in Common NOS1AP Variants [50]  
  Albert-Jan LHJ Aarnoudse, Christopher Newton-Cheh, Andre G Uitterlinden, Bruno HCh Stricker. (Netherlands)

- **2:00pm**  
  - Influence of CYP2D6 Polymorphism on Dose and Switching of Antidepressants [51]  
  Monique J Bijl, Loes E Visser, Ron HN van Schaik, Arnold G Vulto, Teun van Gelder, Bruno HCh Stricker. (Netherlands)

- **2:15pm**  
  - VKORC1, APOE, CYP2C9 Variants and Their Influences on Warfarin Dosing in African Americans [52]  
  H Schelleman, Z Chen, C Kealey, AS Whitehead, J Christie, M Price, CM Brensinger, CW Newcomb, CF Thorn, FF Samaha, SE Kimmel. (United States)

- **2:30pm**  
  - Association between the Genetic Variations on DRD2 and the Risk of Tardive Dyskinesia: A Meta-Analysis Study [53]  
  Huei-Ting Tsai. (United States)

- **2:45pm**  
  - Canadian National Active Surveillance Network for Adverse Drug Reactions: Genotypic Approaches to Therapy in Children (GATC): The First Year [54]  
  BC Carleton, D Warn, S Stenton, R Rassekh, MA Smith, B Dhami, C Ross, MR Hayden. (Canada)
### Pediatrics / Centre 301AB /
**Moderators:** William Cooper & Patricia Saddier

**1:30pm**
- **Diagnosing a Child as Being Asthmatic Does Not Drive Prescribing of Asthma Medication [43]**
  Mira G Zuidgeest, Madelon Bracke, Henriette A Smit, Liset van Dijk, Bert Brunekreef, Hubert G Leufkens. (Netherlands)

**1:45pm**
- **Psychotropic Treatment among Youths Newly Diagnosed with Attention Deficit/Hyperactivity Disorders (ADHD) [44]**
  Chih-Ying Chen, Almut G Winterstein. (United States)

**2:00pm**
- **Safety of Methylphenidate Versus Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) [45]**
  Almut G Winterstein, Tobias Gerhard, Julie Zito, Jonathan Shuster, Arwa Saidi. (United States)

**2:15pm**
- **Mortality Associated with ADHD Drug Treatment [46]**
  Suzanne McCarthy, Macey Murray, Noel Cranswick, Ian Wong. (United Kingdom)

**2:30pm**
- **Young Age at Diabetes Diagnosis Associated with an Increased Risk of Related Serious Adverse Events [47]**
  Annie Hutchison, Esi Ikazoboh, David Russel-Jones, Corinne de Vries. (United Kingdom)

**2:45pm**
- **Trends in Pseudoephedrine Use among U.S. Children 1999-2006: Results from the Slone Survey [48]**
  Louis Vernacchio, Judith P Kelly, David W Kaufman, Lynn Rosenberg, Allen A Mitchell. (United States)

### Aspects of Patient Safety / Centre 302AB /
**Moderators:** Toine Egberts, FISPE, & Juergen Dinjer

**1:30pm**
- **Frequency and Potential Risk Factors of Hospital Admissions Related to Medication (HARM) in the Netherlands [55]**
  Anne J Leendertse, Toine CG Egberts, Patricia MLA van den Bemt. (Netherlands)

**1:45pm**
- **Medication Errors: Impact of Prescribing and Transcription Errors on Preventable Harm in Hospitalised Patients [56]**
  Jasperien E van Doormaal, Patricia MLA van den Bemt, Peter GM Mol, Rianne J Zaal, Antoine CG Egberts, Flora M Haaijer-Ruskamp, Jos GW Kosterink. (Netherlands)

**2:00pm**
- **Warning: Avoid Alcohol While Taking This Medication. The Prevalence and Correlates of Non-Compliers [57]**
  Jessica J Jalbert, Kate L Lapane, Brian J Quilliam. (United States)

**2:15pm**
- **Can Disproportionality Analysis Play a Role in Monitoring Medical Device Safety? [58]**
  Hesha J Duggirala, Xionghu Yang, Robbert P Van Manen. (United States)

**2:30pm**
- **A General Population Based Study of the Impact of Prescription-Only Medicines on the Risk of Road Traffic Accident [59]**
  Jack E Gibson, Richard B Hubbard, Christopher JP Smith, Laila J Tata, John Britton, Andrew W Fogarty. (United Kingdom)

**2:45pm**
- **Ongoing Spontaneous Reporting of Established Drug-Drug Interactions [60]**
  Johanna Strandell, Andrew Bate, Marie Lindquist, I Ralph Edwards, SFINX Group. (Sweden)

### Effectiveness and Safety of Cardiovascular Medications / Centre 303AB /
**Moderators:** Jacques LeLorier, FISPE, & Michael Fischer

**1:30pm**
- **Improvements in Long-Term Mortality after Myocardial Infarction Can Be Explained by Increased Use of Cardiovascular Drugs after Discharge: A 10-Year Trend Analysis among the Community Dwelling Elderly [37]**
  Soko Setoguchi, Murray A Mittleman, Raisa Levin, Wolfgang C Winkelmayer. (United States)

**1:45pm**
- **Improved Treatment and Reduced Mortality in Patients with Acute Coronary Syndrome Using a Guideline-Based Critical Pathway [38]**
  John C Corbelli, David M Janicke, Tracey Hoy, Mark J Cziraky. (United States)
Pharmacoepidemiology and Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

- Free online access for ISPE members
- Latest Impact Factor: 2.155 (JCR 2006)

A selection of the top-cited papers from the 2006 Volume (15)

- A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience (April 2006)
  Lawrence Goldkind, Loren Laine

- Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics (May 2006)
  Sebastian Schneeweiss

- Estimates of acetaminophen (paracetamol)-associated overdoses in the United States (June 2006)
  Parvash Nourjah, Syed Rizwanuddin Ahmad, Claudia Karwoski, Mary Willy

- Methods for evaluation of medication adherence and persistence using automated databases (August 2006)
  Susan E. Andrade, Kristjan H. Kahler, Feride Frech, K. Arnold Chan

- Increasing deaths from opioid analgesics in the United States (September 2006)
  Leonard J. Paulozzi, Daniel S. Budnitz, Yongli Xi

For more information on these top papers and other journal features, please visit

www.interscience.wiley.com/journal/pds
AGENDA Monday, August 20

Effectiveness and Safety of Cardiovascular Medications (Cont.)

2:00pm
• Analyzing Comparative Effectiveness Using Inverse Probability-Weighted Estimators: Evidence-Based vs. Non-Evidence-Based Beta-Blockers To Treat Heart Failure [39]
  K Anstrom, L Curtis, M Massing, D Pelter, A Hernandez, C Dupree, J Kramer. (United States)

2:15pm
• The Contribution of Observational Studies to the Knowledge of Drug Effectiveness in Heart Failure [40]
  Daniela Dobre, Dirk J van Veldhuisen, Mike JL de Jongste, Eric van Sonderen, Ola H Klungel, Robbert Sanderman, Adelita V Ranchor, Flora M Haaijer-Ruskamp. (Netherlands)

2:30pm
• Declining Public Health Burden of Digoxin Toxicity from 1991 to 2004 [41]
  Kevin Haynes, Dan F Heitjan, Sean Hennessy. (United States)

2:45pm
• Beta-Blockers, Other Antihypertensives and Psoriasis [42]
  Yolanda B Brauchli, Susan S Jick, Christoph R Meier. (Switzerland)

3:00 - 3:30pm / Centre 400A /
Break/Posters/Exhibits

3:30 - 5:00pm
CONCURRENT SESSIONS

  Chair: Yola Moride, FISPE
  • Gerald Del Pan, USA, US FDA
  • Akira Kawahara, Japan, Pharmaceuticals and Medical Devices Agency (PMDA)
  • June Raine, Europe, Medicines and Healthcare Products Regulatory Agency (MHRA), & Pharmacovigilance Working Party (EMEA)
  • Maurica Maher, Canada, Health Canada

  • Tjeerd P van Staa, Frank de Vries, John Parkinson, Hubert GM Leufkens. (United Kingdom)

SYMPOSIUM: Pharmacogenetics (PG) for Epidemiologists: What We Know and What We Need to Know [153] / Centre 301AB /
  • Richard B Kim, Canada, University of Western Ontario
  • Geoffrey Liu, Canada, University of Toronto
  • Wei Zhou, USA, CDC
  • Robert Ball, USA, US FDA
  • Andrew Freeman, USA, National Cancer Institute/National Institutes of Health
  • David P Miller, RTI Health Solutions

WORKSHOP: Placebo-based Study Methods for the Quantification of Postmarketing Risk [152] / Centre 302AB /
  • Gerald Faich, Kelly Posner, John Clark. (United States)

SYMPOSIUM: Prescribing Quality Indicators in Research and Practice [155] / Centre 303AB /
  • Jerry Avorn, Bjorn Wettermark, Sean McBride-Stewart, Debra Rowett, Flora M Haaijer-Ruskamp. (Netherlands)

5:00 - 6:00pm
ISPE Council Meetings
Open to all interested participants
  • Academic / Hilton Dufferin / 
  • Government/Regulatory / Hilton Beauport / 
  • Industry / Hilton Plaines / 

6:00 - 8:00pm
PDS Editorial Board / Hilton Villaray / 
(By Invitation)

7:00pm - 10:00pm
Student Social Event – A Night Out in Québec City
  • Meet in Hilton lobby at 7:00pm.
  • Open to all students.
  Organized by the ISPE Student Council
AGENDA: Tuesday, August 21

7:00 - 8:00am / Centre 400A / Poster Session B Set-up

7:00 - 8:00am / Hilton Vieux-Port / CERTs Roundtable [548] (The Centers for Education & Research on Therapeutics)
- Hugh Tilson, Sean Hennessy, Anne Trontell (invited). (United States)
- Open to all participants

7:30 - 8:00pm / Centre Foyer 4 / Registration

8:00 - 5:00pm / Centre 201C / Speakers’ Ready Room

8:00 - 5:00pm / Centre 400A / Exhibits/Posters

8:00 - 9:30am / Centre 200AB / PLENARY SESSION
How Do Our Annual Influenza Vaccines Measure Up? [145]

Chair: M. Miles Braun, FISPE, US FDA

Presenter:
- Gaston De Serres, Institut National de Santé Publique du Québec, Important Impact of Study Design on Vaccine Effectiveness Estimates
  Discussant: Ken Rothman, RTI Health Solutions.

Presenter:
- Edward Belongia, Marshfield Clinic, Substantial Year to Year Variation in Influenza Vaccine Effectiveness and Antigenic Match
  Discussant: David Shay, US Centers for Disease Control and Prevention.

Presenter:
- Lisa Jackson, Group Health Cooperative, Big Bias in Estimates of Influenza Vaccine Effectiveness
  Discussant: Robert Glynn, Harvard University.

Real Data
As an independent subsidiary of the largest US health network by membership, we leverage millions of patient data years every day.

Real Time
Our network’s expanding regional datasets and HealthCore’s ability to integrate medical charts and surveys with claims help you understand “how” and “why” faster than ever.

Real World
We can simply report and publish what we’ve found, create evidence-based decision tools, and/or help educate your internal and external customers on what the study means.

Real Insight
Our staff of clinicians, epidemiologists, biostatisticians and strategists participate in many efforts to identify risk and improve the quality of care.

Ask us how we can draw on our firm’s ten years of experience for a custom solution for your needs.

For more information, contact Mark Cziraky: (302) 230-2110 or mcziraky@healthcore.com
Visit our Web site: www.healthcore.com
AGENDA · Tuesday, August 21

Annual Meeting of ISPE Members & Awards Ceremony

**Annual Meeting of ISPE Members**
- Allen A. Mitchell, FISPE, ISPE President
- Corinne de Vries, ISPE Vice President Finance

**Awards Ceremony**

**ICPE 2007**
- Jocelyne Moisan, Chair, Local Host Committee
- Jean-Pierre Grégoire, Chair, 2007 Scientific Program Committee

**Student Awards**
- Presented by Jean-Pierre Grégoire, Chair, 2007 Scientific Program Committee

- **Best Drug Utilization Abstract:** Julie Blouin, University of Montreal, *Impact of Non-Adherence to Bisphosphonates on the Incidence of Osteoporotic Fractures: A Nested Case-Control Study*

- **Best Methods Abstracts:** Dean Eurich, University of Alberta, *Does Incorporating Health-Related Quality of Life Into Composite Outcome Analyses Improve Transparency?*

- **Third Best Abstract:** Marie-Josée Martel, University of Montreal, *Control and Severity of Maternal Asthma During Pregnancy and the Incidence of Allergic Rhinitis and Atopic Dermatitis in the Offspring*

- **Second Best Abstract:** Albert Jan Aarnoudse, Erasmus Medical Center, *Increased QTc Shortening to Digoxin in Common NOS1AP Variants*

- **Edlavitch Award:** Diane van Wieren-de Wijer, Utrecht University, *Interactions Between the Gly460Trp Alpha-Adducin Gene Variant and Diuretics and the Risk of Myocardial Infarction Among Treated Hypertensive Patients*

**Induction of ISPE Fellow (FISPE)**
- Sean Hennessy, FISPE, Chair, Fellowship & Awards Committee
- **Inductee:** Rhonda L. Bohn, FISPE

**ISPE-PDS Prizes**
- Presented by Sean Hennessy, FISPE, Associate Editor, *Pharmacoepidemiology & Drug Safety*, and Richard Hughes, Managing Editor, *Pharmacoepidemiology & Drug Safety*

- **Prize winners for best paper published in PDS Volume 15 (2006):**
  - Anita K. Wagner, FDA Drug Prescribing Warnings: Is The Black Box Half Empty or Half Full?

- Priscilla Velentgas, *Cardiovascular Risk of Selective Cyclooxygenase-2 Inhibitors and Other Non-Aspirin Non-Steroidal Anti-Inflammatory Medications*

**Annual Meeting of ISPE Members & Awards Ceremony**

**Methods II**
- **Moderators:** Ken Rothman, FISPE

- **11:00am**
  - Increasing Restriction in Database Studies of Elderly Drug Use: Comparison with Randomized Trial Results [61]
  - Sebastian Schneeweiss, Amanda Patrick, Til Stürmer, Alan Brookhart, Jerry Avorn, Kenneth Rothman, Malcolm Maclure, Robert Glynn. (United States)

- **11:15am**
  - Does Incorporating Health-Related Quality of Life into Composite Outcome Analyses Improve Transparency? [62]
  - Dean T Eurich, Sumit R Majumdar, Finlay A McAlister, Ross T Tsuyuki, Yutaka Yasui, Jeffrey A Johnson. (Canada)

- **11:30am**
  - A Review of PRR over Time Analyses for Various Drugs with Serious Adverse Event Risks Unknown at Drug Launch [63]
  - Keith L Altman. (United States)

- **11:45am**
  - Risk Indices Based on Administrative Data Failed To Control for Confounding Caused by Healthy User Bias [64]
  - Michael Jackson, Jennifer Nelson, Lisa Jackson. (United States)

- **12:00pm**
  - Estimating Effects of Antihypertensive Therapy on Adverse Outcomes in the Presence of Time-Dependent Confounding by Blood Pressure [65]
  - Tobias Gerhard, Almut Winterstein, Jonathan Shuster, Julie Johnson, Abraham Hartzema, Carl Pepine. (United States)

**10:30 - 11:00am**

**11:00 - 12:30pm**

Concurrent Sessions – Contributed Papers

**Methods II**
- **Centre 200AB**
- **Moderators:** Ken Rothman, FISPE

- **11:00am**
  - Increasing Restriction in Database Studies of Elderly Drug Use: Comparison with Randomized Trial Results [61]
  - Sebastian Schneeweiss, Amanda Patrick, Til Stürmer, Alan Brookhart, Jerry Avorn, Kenneth Rothman, Malcolm Maclure, Robert Glynn. (United States)

- **11:15am**
  - Does Incorporating Health-Related Quality of Life into Composite Outcome Analyses Improve Transparency? [62]
  - Dean T Eurich, Sumit R Majumdar, Finlay A McAlister, Ross T Tsuyuki, Yutaka Yasui, Jeffrey A Johnson. (Canada)

- **11:30am**
  - A Review of PRR over Time Analyses for Various Drugs with Serious Adverse Event Risks Unknown at Drug Launch [63]
  - Keith L Altman. (United States)

- **11:45am**
  - Risk Indices Based on Administrative Data Failed To Control for Confounding Caused by Healthy User Bias [64]
  - Michael Jackson, Jennifer Nelson, Lisa Jackson. (United States)

- **12:00pm**
  - Estimating Effects of Antihypertensive Therapy on Adverse Outcomes in the Presence of Time-Dependent Confounding by Blood Pressure [65]
  - Tobias Gerhard, Almut Winterstein, Jonathan Shuster, Julie Johnson, Abraham Hartzema, Carl Pepine. (United States)

**10:30 - 11:00am**

**11:00 - 12:30pm**

Concurrent Sessions – Contributed Papers

**Methods II**
- **Centre 200AB**
- **Moderators:** Ken Rothman, FISPE

- **11:00am**
  - Increasing Restriction in Database Studies of Elderly Drug Use: Comparison with Randomized Trial Results [61]
  - Sebastian Schneeweiss, Amanda Patrick, Til Stürmer, Alan Brookhart, Jerry Avorn, Kenneth Rothman, Malcolm Maclure, Robert Glynn. (United States)

- **11:15am**
  - Does Incorporating Health-Related Quality of Life into Composite Outcome Analyses Improve Transparency? [62]
  - Dean T Eurich, Sumit R Majumdar, Finlay A McAlister, Ross T Tsuyuki, Yutaka Yasui, Jeffrey A Johnson. (Canada)

- **11:30am**
  - A Review of PRR over Time Analyses for Various Drugs with Serious Adverse Event Risks Unknown at Drug Launch [63]
  - Keith L Altman. (United States)

- **11:45am**
  - Risk Indices Based on Administrative Data Failed To Control for Confounding Caused by Healthy User Bias [64]
  - Michael Jackson, Jennifer Nelson, Lisa Jackson. (United States)

- **12:00pm**
  - Estimating Effects of Antihypertensive Therapy on Adverse Outcomes in the Presence of Time-Dependent Confounding by Blood Pressure [65]
  - Tobias Gerhard, Almut Winterstein, Jonathan Shuster, Julie Johnson, Abraham Hartzema, Carl Pepine. (United States)

**10:30 - 11:00am**

**11:00 - 12:30pm**

Concurrent Sessions – Contributed Papers

**Methods II**
- **Centre 200AB**
- **Moderators:** Ken Rothman, FISPE

- **11:00am**
  - Increasing Restriction in Database Studies of Elderly Drug Use: Comparison with Randomized Trial Results [61]
  - Sebastian Schneeweiss, Amanda Patrick, Til Stürmer, Alan Brookhart, Jerry Avorn, Kenneth Rothman, Malcolm Maclure, Robert Glynn. (United States)

- **11:15am**
  - Does Incorporating Health-Related Quality of Life into Composite Outcome Analyses Improve Transparency? [62]
  - Dean T Eurich, Sumit R Majumdar, Finlay A McAlister, Ross T Tsuyuki, Yutaka Yasui, Jeffrey A Johnson. (Canada)

- **11:30am**
  - A Review of PRR over Time Analyses for Various Drugs with Serious Adverse Event Risks Unknown at Drug Launch [63]
  - Keith L Altman. (United States)

- **11:45am**
  - Risk Indices Based on Administrative Data Failed To Control for Confounding Caused by Healthy User Bias [64]
  - Michael Jackson, Jennifer Nelson, Lisa Jackson. (United States)

- **12:00pm**
  - Estimating Effects of Antihypertensive Therapy on Adverse Outcomes in the Presence of Time-Dependent Confounding by Blood Pressure [65]
  - Tobias Gerhard, Almut Winterstein, Jonathan Shuster, Julie Johnson, Abraham Hartzema, Carl Pepine. (United States)
Effectiveness of Statins on Intended and Not Intended Outcomes  / Centre 205AB  /  
Moderators: Jim Kaye & Olaf Klugel

11:00am
- A Systematic Review on the Therapeutic Equivalence of Statins [85]
  Der-Chang Wung, Yea-Huei Kao, Swu-Jane Lin, Shu-Hwa Tai. (Taiwan)

11:15am
- Therapeutic Substitution of Statins: A Real World Data Driven Approach Based on NCEP ATPIII Low Density Lipoprotein Cholesterol (LDL-C) Goals [86]
  Vincent Willey, Brian Sweet, Christy Fang, Mark Cziraky. (United States)

11:30am
- Daily Medication Adherence and Dose Changes on the Effectiveness of Statin Therapy in LDL Cholesterol Change [87]
  Elizabeth V Lawler, David R Gagnon, Richard E Scranton. (United States)

11:45am
- The Effect of Changes in Statin Prescribing on Secondary Prevention after the First Acute Myocardial Infarction [88]
  Stella S Daskalopoulou, Joseph A Delaney, Kristian B Filion, James M Brophy, Nancy E Mayo, Samy Suissa. (Canada)

12:00pm
- Effectiveness of Statins for the Prevention of Keratinocyte Carcinomas [89]
  David D Dore, Kate L Lapane, Vincent Mor, Amal N Trivedi, Martin A Weinstock. (United States)

12:15pm
- Statins and Cancer Risk [90]
  Igor Karp, Hassan Behlouli, Jacques LeLorier, Louise Pilote. (Canada)
Psychotropics: To Die, To Sleep, Per Chance to Dream
/ Centre 301AB /
Moderators: Jan Willem van der Velden, FISPE, & Adrianne Einarson

11:00am
• Cardiovascular and Infection-Related Morbidity and Mortality in Conventional vs. Atypical Antipsychotic Medications in the Elderly [73]
  Soko Setoguchi, Philip S Wang, Alan M Brookhart, Claire F Canning, Sebastian Schneeweiss. (United States)

11:15am
• The Temporal Relationship between Antipsychotic Use and Stroke among Community-Dwelling Elderly: Further Support for a Causal Relationship [74]
  Bart C Kleijer, Rob J Van Marum, Wiilma Knol, Antoine C Egberts, Eibert R Heerdink. (Netherlands)

11:30am
• The Incidence of Diabetes in Atypical Antipsychotic Users Differs According to Agent – Results from a Multisite Epidemiologic Study [75]
  Marianne Ulcickas Yood, Gerald deLorenze, Charles P Quesenberry, Jr., Gilbert L'Italien, Susan A Oliveria, Al-Lin Tsai, Ulka Campbell, Vincent Willey, Robert McQuade, John Newcomer. (United States)

11:45am
• Safety of Central Nervous System Stimulants in Youths with Attention-Deficit/Hyperactivity Disorder (ADHD) [76]
  Almut G Winterstein, Tobias Gerhard, Jonathan Shuster, Julie M Zito, Michael Johnson, Arwa Saidi. (United States)

12:00pm
• Psychotropics in French Children and Adolescents: Utilization Patterns and Safety Issues [77]
  Christine Sevilla-Dedieu, Viviane Kovess-Masfety. (France)

12:15pm
• The Impact of Benzodiazepine Use on Mobility in Community Dwelling Elderly [78]
  Robert M Boudreau, Yazan F Roumani, Joseph T Hanlon, Anne B Newman, Stephanie A Studenski, Tamara B Harris, Michael C Nevitt, Ronald I Shorr, Eleanor M Simonsick. (United States)

Going A “Lung” Way / Centre 302AB /
Moderators: Daniel Mines & Lucie Blais

11:00am
• Oral Corticosteroids and Mortality Following Hip Fracture: A Population-Based Cohort Study [79]
  Cynthia de Luise, Michael Brimacombe, Lars Pedersen, Henrik T Sørensen. (United States)

11:15am
• Control and Severity of Maternal Asthma during Pregnancy and the Incidence of Allergic Rhinitis and Atopic Dermatitis in the Offspring [80]
  Marie-Josee Martel, Marie-France Beauchesne, Jean-Luc Malo, Evelyne Rey, Sylvie Perreault, Amelie Forget, Lucie Blais. (Canada)
  *Student Award Recipient-Third Best Abstract

11:30am
• Revisiting the Steroids-Oral Cleft Controversy [81]
  Carol Louik, Michael Schatz, Sonia Hernandez-Diaz, Martha M Werler, Allen A Mitchell. (United States)

11:45am
• Evidence for No Association between Use of beta-2-Agonists and Risk of Acute Myocardial Infarction in Patients with Hypertension [82]
  Frank de Vries, Sander Pouwels, Madelon Bracke, Olaf Klungel, Jan-Willem Lammers, Hubert Leufkens, Tjeerd van Staa. (Netherlands)

12:00pm
• Maternal Asthma Medication Use before and during Pregnancy [83]
  Faranak Firoozi, Catherine Lemiere, Marie-France Beauchesne, Francine M Ducharme, Anick Berard, Lucie Blais. (Canada)

12:15pm
• Clinical Impact of an Integrated Care Program in Asthma: The RESPIRE Study [84]
  Marie-Sophie Jobin, Jocelyne Moisan, Nancy Manzerolle, Yves Bolduc, Eileen Dorval, Madone Turcotte, Louis-Philippe Boulet, Jean-Pierre Gregoire. (Canada)
Health Care Policy / Centre 303AB /

Moderators: Tom Einarson, FISPE, & Niteesh Chowdry

11:00am
• The Impact of Cost Sharing on a Patient Compliance and Persistence for Smoking Cessation Pharmacotherapy [67]
  Diana Brixner, Carmen Kirkness, Scott Robinson, Eva Lydick. (United States)

11:15am
• Impact of E-Prescribing on Medication Use and Cost in Community-Based Practices [68]
  MA Fischer, TG Ferris, C Vogeli, M Stedman, MA Brookhart, JS Weissman. (United States)

11:30am
• The Effect of Epoetin Dose on Haematocrit Response: Implications for Health Policy [69]
  Dennis Cotter, Yi Zhang, Mae Thamer, James Kaufman, Miguel Herman. (United States)

11:45am
• The Effect of Medicare Part D on the Utilization of Essential Drugs by Seniors without Prior Drug Coverage [70]
  Sebastian Schneeweiss, Amanda R Patrick, Alex Pedan, Laleh Varasteh, Raia Levin, William Shrank. (United States)

12:00pm
• Alternatives to Project-Specific Consent for Access to Personal Information for Health Research: Canadian Public Opinion [71]
  Don Willison, Lisa Schwartz, Julia Abelson, Cathy Charles, Marilyn Swinton, David Northrup, Lehana Thabane. (Canada)

12:15pm
• Innovation Drives Orphan Drug Development [289]
  Harald E Heemstra, Remco LA de Vrueh, Sonja van Weely, Hubert GM Leufkens. (Netherlands)

12:30 - 2:00pm
Lunch/Poster Session B/Exhibits / Centre 400A /

ISPE Committee Meetings
Open to all interested participants.
(Lunch will be available in meeting rooms)

• Development / Hilton Orleans /
• Global Development / Hilton Villeray /
• Membership / Hilton Lauzon /
• Publications / Hilton Sillery /

23rd ICPE August 19-22, 2007 Québec City Convention Centre
2:00 - 3:30pm
CONCURRENT SESSIONS – CONTRIBUTED PAPERS

The Benefits of Adherence / Centre 200AB /
Moderators: Lynn Bosco & Monique Elseviers

2:00pm
• Impact of Non-Adherence to Bisphosphonates on the Incidence of Osteoporotic Fractures: A Nested Case-Control Study [91]
  Julie Blouin, Alice Dragomir, Yola Moride, Louis-Georges Ste-Marie, Julio C Fernandes, Sylvie Perreault. (Canada)
  *Student Award Recipient – Best Drug Utilization Abstract

2:15pm
• Impact of Statin Adherence on Chronic Heart Failure among Patients Newly Treated for Primary Prevention [92]
  Sylvie Perreault, Alice Dragomir, Lucie Blais, Lyne Lalonde, Anick Bérard, Michel White. (Canada)

2:30pm
• Non-Persistent Use of Antihypertensive Drugs Increases Risk of Hospitalizations for Acute Myocardial Infarction by 10% in Patients with Low or Intermediate Cardiovascular Risk [93]

2:45pm
• Impact of Medication Adherence on Health Care Cost among Patients Newly Treated with Antihypertensive Agents for Primary Prevention [94]
  Sylvie Perreault, Alice Dragomir, Lucie Blais, Lyne Lalonde, Anick Bérard. (Canada)

3:00pm
• Adherence to Gastroprotection and the Risk of NSAID-Related Upper Gastrointestinal Complications [95]
  Eva M van Soest, Miriam CJM Sturkenboom, Jeanne P Dieleman, Katia MC Verhamme, Peter D Siersema, Ernst J Kuipers. (Netherlands)

3:15pm
• Prospective Assessment of Risk Factors for Warfarin Nonadherence: The Program for the Reduction in Medical Errors (PRIME) Study [96]
  AB Platt, AR Localio, JD Christie, CM Brensinger, R Gross, A Cohen, M Price, JP Metlay, BL Strom, SE Kimmel. (United States)

Hematology / Centre 205AB /
Moderators: Alec Walker, FISPE, & Mitchell Levine

2:00pm
• Hormonal Contraceptives and Risk of Aneurysmatic Subarachnoid Haemorrhage [103]
  R Risselada, A van der Lugt, WJ Niessen, MCJM Sturkenboom. (Netherlands)

2:15pm
• Effect of Oral Antiplatelet Drugs on Major Bleeding among Users of Coumarin Anticoagulants [104]
  Tom Schalekamp, Olaf H Klungel, Patrick C Souverein, Anthonius de Boer. (Netherlands)

2:30pm
• Case-Finding of Possible Heparin-Induced Thrombocytopenia in an Academic Teaching Hospital by Linking Laboratory and Medication Data [105]
  Maarten ten Berg, Albert Huisman, Patricia van den Bemt, Fred Schobben, Toine Egberts, Wouter van Solinge. (Netherlands)

2:45pm
• Preadmission Oral Anticoagulant Therapy and 30-Day Mortality from Peptic Ulcer Bleeding [106]
  Pernille Larsen, Steffen Christensen, Else Tønnesen, Søren P Johnsen, Reimar W Thomsen, Henrik T Sørensen. (Denmark)

3:00pm
• Anti-Thrombotic Drug-Drug Interactions and the Risk of Gastro-Intestinal Bleeding [107]
  Joseph A Delaney, Lucie Opatrny, James M Brophy, Samy Suissa. (Canada)

3:15pm
• Non-Chemotherapy Drug-Induced Agranulocytosis: A Systematic Review of Case Reports [108]
  Frank Andersohn, Christine Konzen, Edeltraut Garbe. (Germany)
Disease Epidemiology / Centre 301AB /
Moderators: Judith Jones, FISPE, & Elena Rivero, FISPE

2:00pm
- Incidence of Interstitial Pneumonitis in Danish Breast Cancer Patients 1994-2004 [109]
  Steffen Christensen, Lars Pedersen, Miriam Grotja, Annette Beiderbeck, Henrik T Sørensen. (Denmark)

2:15pm
- Mortality in Systemic Lupus Erythematosus [110]
  Alison L Nightingale, Corinne S de Vries. (United Kingdom)

2:30pm
- Co-Existence of Autoimmune Diseases within Individuals [111]
  Emily C Somers, Sara L Thomas, Liam Smeeth, Andrew J Hall. (United States)

2:45pm
- Incidence of Rheumatoid Arthritis in General Practice and its Association with Co-Morbidity and Drug Treatment [112]
  Luis A Garcia Rodriguez, Laura Barreales Tolosa, Mari-Ann Wallander, Saga Johansson, Ana Ruigomez. (Sweden)

3:00pm
- The Effect of Heart Rate and its Changes on Cardiovascular Disease and Mortality [113]
  Efrosini Setakis, Hubert GM Leufkens, Tim J Williams, Tjeerd P van Staa. (United Kingdom)

3:15pm
- Impact of Potential Selection Bias on Prevalence Estimates of Lower Urinary Tract Symptoms in a Primary Care Setting [114]
  Alicia W Gilsenan, Jianmin Wang, Kirk Midkiff, Elizabeth Andrews. (United States)

Miscellaneous / Centre 302AB /
Moderators: Keith Beard, FISPE, & Annie Fourrier

2:00pm
- Brand and Generic Substitution in Australia: Are Patients Switched between Products Multiple Times? [115]
  Lisa Kalisch, Elizabeth Roughead, Andrew Gilbert. (Australia)

2:15pm
- Influenza Vaccinations in Heart Disease: More Socially Deprived Patients Are Less Likely to Receive Their Flu Jab [116]
  Annie Hutchison, Helen E Seaman, Corinne S de Vries. (United Kingdom)

2:30pm
- Effect of Antibiotics Taken for Other Illnesses on Spontaneous Clearance of Helicobacter pylori Infection in Children [117]
  Cheryl S Broussard, Karen J Goodman, Carl V Phillips, Mary A Smith, Lori A Fischbach, Corinne C Aragaki, R Sue Day. (United States)

2:45pm
- Sedation/Analgesic Use for Pediatric Joint Dislocation Injuries Presenting to the Emergency Department [118]
  Joshua H Tamayo-Sarver, Yu Yan, Cherri Hobgood. (United States)

3:00pm
- Timing, Type, and Indication of Anti-Infective Use and Pregnancy Outcomes [119]
  Martha M Werler, Sonia Hernandez-Diaz, Carol Louik, Allen A Mitchell. (United States)

3:15pm
- Association between Antidepressant Use during Pregnancy and Infants Born Small for Gestational Age [120]
  Élodie Ramos, Driss Oraichi, Anick Bérard. (Canada)
Pregnancy and Birth Defects
/Centre 303AB /
Moderators:  Lolkje de Jong - van den Berg & Anick Berard, FISPE

2:00pm
• Prescription Drug Use Before, During and After Pregnancy Among 50,000 Women in Norway in 2004-2005 [97]
  Anders Engeland, Jørgen Bramness, Anne Kjersti Daltveit, Marit Ronning, Svetlana Skurtveit, Kari Furu. (Norway)

2:15pm
• Discontinuation of Antidepressant Medication in Pregnancy and Postpartum Suicide Risk: A Population-Based Cohort of 81,975 Women [98]
  Janet R Hardy, Sybil L Crawford, Tiffany A Moore-Simas, Sherry Pagoto. (United States)

2:30pm
• Sensitivity and Specificity of Computerized Databases for Use of Anti-Infectives Early in Pregnancy [99]
  Sengwee Toh, Allen A Mitchell, Martha M Werler, Sonia Hernández-Díaz. (United States)

2:45pm
• Lost to Follow-Up Rates in Pregnancy Registries by Enrollment Source [100]
  Deborah L Covington, Susan S Roberts, Ann E Mallard. (United States)

3:00pm
• Maternal Use of Loratadine during Pregnancy and Prevalence of Hypospadias in Offspring: A Danish Nationwide Case-Control Study [101]
  Lars Pedersen, Mette Nørgaard, Kenneth J Rothman, Henrik T Sørensen. (Denmark)

3:15pm
• Use of Analgesics Early in Pregnancy and the Risk of Specific Birth Defects [102]
  Sonia Hernández-Díaz, Martha M Werler, Carol Louik, Allen A Mitchell. (United States)

3:30 - 4:00pm / Centre 400A / Break/Posters/Exhibits
5:30 - 6:30pm
Special Interest Group (SIG) Meetings
• Open to all interested participants.
• Drug Utilization/Health Services Research SIG / Hilton Beauport /
• Medications in Pregnancy SIG / Hilton Beaumont/Belair /
• Molecular Epidemiology/Pharmacogenetics SIG / Hilton Courville/Montmorency /

7:30 - Midnight
Evening at the Musée National des Beaux-Arts du Québec
• The Museum is located in the heart of the Plains of Abraham overlooking the Saint Lawrence River. The museum presents exhibits featuring Quebec artists from the past and present. You also will have an opportunity to visit the Baillairgé Pavilion, which used to house the Old Prison on the Plains, and to dance the night away to the music of the David Jacques’ Band.
• Admission by badge or ticket.
• Getting to the museum. Walking: the museum is an easy 20 minutes walk from the Convention Centre along Grand Allee. Bus: buses will shuttle between the Convention Centre and the Museum beginning at 7:00pm.
• Cash bar.

Cutting edge epidemiology contributing to the discovery and development of safe and effective medicines

We are a global team of epidemiologists and other professionals that bring population-based evidence on disease and treatment to influence decision-making from drug discovery through development to medical practice. By designing, analyzing, and interpreting observational information from a public health perspective we play an important role in bringing new medicines to the market. The breadth of our responsibilities includes:

• Analyzing the occurrence and distribution of diseases, including underlying disease process
• Determining the burden of illness and unmet medical need
• Exploring traditional and new risk factors for diseases
• Evaluating the effect of treatment in the real world, including beneficial effects, patterns of drug uses and adverse events
• Detecting opportunities for possible new drug uses and new paths of drug development

Please visit our website at http://epidemiology.gsk.com/organization.html to find out more detailed information about Worldwide Epidemiology at GlaxoSmithKline.

Developing talent through equality of opportunity
7:00 - 8:00am / Centre 400A / Poster Session C Set-up

7:00 - 8:00am / Hilton Panorama/Plaines / 2008 Scientific Program Committee Meeting

7:30am - 4:30pm / Centre Foyer 4 / Registration

8:00am - 3:30pm / Centre 201C / Speakers' Ready Room

8:00am - 1:45pm / Centre 400A / Exhibits/Posters

8:30 - 10:00am

CONCURRENT SESSIONS – CONTRIBUTED PAPERS

NSAIDs and Cardiovascular Risk: Is There Consistency in the Evidence? / Centre 200AB /

Moderators: Elham Rahme & Tjeerd Van Staa

8:30am

- Risk of Stroke in Arthritis Patients Treated with Cox-2 Selective and Non-Selective NSAIDs [139]
  David J Graham, Gurkirpal Singh, H Wang, A Mannalithara, V Lingala, Alka Mithal, George Triadafilopoulos. (United States)

8:45am

- COX-Selectivity of Nonsteroidal Antiinflammatory Drugs and the Risk of Stroke [140]
  Mendel Haag, Monique Breteler, Bruno Stricker. (Netherlands)

9:00am

- NSAID Use and Risk of Myocardial Infarction in U.S. Veterans [141]
  Donald R Miller, David W Kaufman, Michael A Lewis, Elham Rahme, Lynn Rosenberg, Jaques LeLorier, Francesca Cunningham. (United States)

9:15am

- Use of Cox-2 Inhibitors, Other NSAIDs, and the Risk of Myocardial Infarction in Three Populations from UK, Canada, and the US [142]
  Michael A Lewis, Donald R Miller, Elham Rahme, Dörthe Kühl-Habich, Fran Cunningham, David W Kaufman, Lynn Rosenberg, Jaques LeLorier. (Germany)

9:30am

- Analgesic Use and Risk of Cardiovascular Disease in Women [143]
  Tobias Kurth, Gregory Kotler, Julie E Buring, J Michael Gaziano. (United States)

9:45am

- Gastrointestinal and Thromboembolic Events with Etoricoxib: Case Series from a Prescription-Event Monitoring (PEM) Study in England [144]
  Deborah Layton, Vanessa Marshall, Saad AW Shakir. (United Kingdom)

Current Trends in Pharmacovigilance / Centre 205AB /

Moderators: Nicholas Moore, FISPE, & Alina M Fernandez

8:30am

- Estimating the Extent of Adverse Event Reporting to the US Food and Drug Administration: A Case-Study of the Statin-Associated Rhabdomyolysis Data [146]
  Mara McAdams, Judy Staffa, Gerald Dal Pan. (United States)

8:45am

- Risk of Hospitalized Rhabdomyolysis Associated with Lipid Lowering Drugs in a Real World Setting [147]
  Mark Cziraky, Siddhesh Kamat, James McKenney, Vincent Willey, Maxine Fisher, John Guyton, Terry Jacobson, Michael Davidson. (United States)

9:00am

- A Population Based Study of IV Bisphosphonate Therapy and Osteomyelitis or Surgery of the Jaw [148]
  Gregg S Wilkinson, Yong-fang Kuo, Jean L Freeman, James S Goodwin. (United States)

9:15am

- Guidelines for Submitting Adverse Events Reports for Publication [149]
  William N Kelly. (United States)

9:30am

- Missing Data in FDA Adverse Event Reporting Systems [150]
  Sheila Weiss Smith, Victor V Gogolak, Gaurav Deshpande, Stephanie Chung, Shekhar H Mehta. (United States)

9:45am

- A New Quantitative Method for Drug-Drug Interaction Screening in Collections of Individual Case Safety Reports [151]
  Niklas G Norén, Rolf Sundberg, Andrew Bate, Ralph I Edwards. (Sweden)
Measurement Methods / Centre 301AB / Moderators: Til Sturmer, FISPE & Gergana Zletava

8:30am
• Medicine Use Among 11- and 13-Year-Olds: Agreement between Parents’ Reports and Children’s Self-Reports [121]
  Anette Andersen, Rikke Krolner, Bjorn E Holstein, Pernille Due, Ebba H Hansen. (Denmark)

8:45am
• The Validity of Self-Reported Prescription Medication Use among Adolescents Varied by Therapeutic Class. A Comparison of Questionnaire Survey and Prescription Database [122]
  Svetlana Skurtveit, Randi Selmer, Aage Tverdal, Kari Furu. (Norway)

9:00am
• Assessing the Validity of an Approach Dealing with Missing Drug Information in the Saskatchewan Prescription Drug Plan Database [123]
  Hani M Tamim, Vicky Tagalakis. (Saudi Arabia)

9:15am
• Evaluation of Health Insurance Claims as a Method for Identifying Patients with Systemic Lupus Erythematosus [124]
  Patricia M Eng, Lisa B Weatherby, Judy Wong, Pavel Napalkov, Wei Dong, Alexander M Walker. (United States)

9:30am
• Empirical Evaluation of Statistical Approaches for Analyzing Physician-Randomized Quality Improvement Interventions [125]
  Margaret R Stedman, David R Gagnon, Robert A Lew, Daniel H Solomon, M Alan Brookhart. (United States)

9:45am
• A New Sample Size Formula Useful for Case-Cohort Studies [126]
  Akira Wakana, Kiyoshi Kubota. (Japan)

Drug Utilization Potpourri / Centre 302AB / Moderators: Bjorn Wettermark & Jesper Hallas

8:30am
• Onset and Offset of Fracture Benefits Associated with Bisphosphonate Use [133]
  Ariene M Gallagher, Stephan Rietbrock, Melvin Olson, Hubert GM Leufkens, Tjeerd P van Staa. (United Kingdom)

8:45am
• Non-Steroidal Anti-Inflammatory Drug (NSAID) Utilization Factors in the Netherlands [134]
  Deborah Layton, Patrick C Souverein, Eibert R Heerdink, Toine CG Egberts, Saad AW Shakir. (United Kingdom)

9:00am
• A Comparison of the Impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Trial on Prescribing Patterns in Canada and the United States [135]
  Niteesh K Choudhry, Brandon Zagorski, Raisa Levin, Kathy Sykora, Jerry Avorn, Andreas Laupacis, Muhammad M Mamdani. (United States)

9:15am
• Data Collection Agreement in Pharmacoepidemiology: Comparison of Patients, Physician and Database Sources [136]
  Fanny Depont, Regis Lassalle, Cuong Huynh Minh, Cecile Droz, Abdellah Abouelfath, Patrick Blin, Nicholas Moore, Annie Fourrier-Réglat. (France)

9:30am
• Multi-Day Lapses in Drug Dosing: Incidence and Durations in a Database of >20000 Ambulatory Patients’ Electronically Compiled Drug Dosing Histories [137]
  Bernard Vrijens, Anne-Catherine Lange, John Urquhart. (Belgium)

9:45am
• The Australian Rise of Esomeprazole – Is Expenditure on Samples a Contributor? [138]
  Greg Kyle, Lisa Nissen, Sue Tett. (Australia)
Vaccine and Antiinfective Safety
Issues Centre / 303AB /
Moderators: Xavier Kurz & Bob Ball

8:30am
• Hepatitis B Vaccination and the Risk of Childhood Onset Multiple Sclerosis [127]
  Yann Mikaeloff, Guillaume Caridade, Melanie Rossier, Samy Suissa, Marc Tardieu. (France)

8:45am
  Penina Haber, Hector Izurieta, Manish Patel, James Baggs, Parashar Umesh. (United States)

9:00am
• Infliximab Use in Patients with Inflammatory Bowel Disease and the Risk of Serious Bacterial Infections [129]
  Sebastian Schneeweiss, Daniel Solomon, Joshua Korzenik, Claire Canning, Brian Bressler. (United States)

9:15am
• Evaluation of Occurrence of Guillain-Barré Syndrome among Recipients of Influenza Vaccine in 2000 and 2001 [130]
  Dale R Burwen, Robert Ball, Wilson W Bryan, Hector S Izurieta, Lawrence La Voie, Neville Gibbs, Rebecca Kliman, M Miles Braun, Team. (United States)

9:30am
• A Pharmacoepidemiological Study of the Risk of Severe Hepatic Injury in Users of Telithromycin and Clarithromycin [131]
  Andrew T McAfee, Alexander M Walker. (United States)

9:45am
• Racial Differences in Discontinuation of Efavirenz Treatment [132]
  Mirjam-Colette Kempf, Maria Pisu, Anastasiya Maherya, Andrew O Westfall, Gretchen Cloud, Michael S Saag. (United States)

10:00 - 10:30am / Centre 400A /
Break/Posters/Exhibits

10:30 - Noon
CONCURRENT SESSIONS

SYMPOSIUM: Selective Serotonin Reuptake Inhibitors (SSRIs) and Birth Defects [549] / Centre 200AB /
• Sonia Hernández-Diaz, John Seeger, Jennita Reefhuis, Carol Louik. (United States)

WORKSHOP: Introducing Doubly Robust Estimation of Treatment Effects [164] / Centre 205AB /
• Michele Jonsson Funk. (United States)

• Boris L Van Wijk, Alan M Brookhart, Suzanne M Cadarette, Amanda R Patrick, John Urquhart. (Netherlands)

• Rhonda L Bohn, Nancy A Dreyer, Kathryn Starzyk, Elizabeth B Andrews, Joseph Singer. (United States)

SYMPOSIUM: Risk Management Planning [165] / Centre 303AB /
• Patrick Waller, Saad Shakir, June Raine, Susana Perez-Gutthann, Sally Lettis, Gerald Faich. (United Kingdom)

Noon - 1:30pm / Centre 400A /
Lunch/Poster Session C/Exhibits

ISPE Board of Directors Luncheon / Hilton Panorama/Vieux-Port /
• By Invitation

1:30 - 2:30pm / Centre 200AB /
INVITED PLENARY
• Samy Suissa, Newest Methods in Pharmacoepidemiology: Back to Basics and Beyond
2:30 - 4:00pm / Centre 200AB / 
HOT TOPICS SESSION
Pharmaceutical Risk Management in a Generic Rich Environment

- Hubert GM Leufkens, FISPE, Chair
- June Raine, MHRA/EMEA
- Andrew Fox, Amgen
- Allen A. Mitchell, FISPE
- Colin D’Cunha, Apotex, Inc.

Who is responsible or 'owns' a safety issue in a generic rich market, particularly in the context of individual drug risks versus class effects?
Are producers of generic pharmaceuticals providing enough funding for research on questions related to drug safety?

What about harmonization of safety sections of SmPCs and other information sources?
Who takes responsibility for risk management programs when generics enter the market, e.g. isotretinoin and teratogenicity prevention?

How to handle inappropriate linkage of generic drug related safety issue to innovator products, e.g. in case of biosimilars.

4:00 - 4:30pm / Centre 200AB /
The Final Word
Poster Awards
- Lolkje T. de Jong-van den Berg
Chair, Poster Awards Committee

ICPE 2008–Copenhagen, Denmark
- Jesper Hallas,
Chair, 2008 Scientific Program Committee

Adjournment of ICPE 2007